Antony Loebel, MD

Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder: A Randomized, Double-blind, Fixed-dose Trial

Background: In a previous flexible dose study, dasotraline, a long-acting dopamine/ norepinephrine reuptake inhibitor, demonstrated significant efficacy in the treatment of binge-eating d...

Joyce Tsai , PhD;

Justine Kent , MD;

Antony Loebel , MD;

Robert Goldman , PhD;

Brad Navia , MD, PhD;

James Hudson , MD;

Carlos Grilo , PhD;

Susan McElroy , MD;

Ling Deng , PhD;

11/22/2019

Hospitalization Risk in Pediatric Bipolar Patients Treated with Lurasidone vs. Other Oral Atypical Antipsychotics: A Real-World Retrospective Claims Database Study

Background: Real-world evidence on atypical antipsychotic (AAP) use in pediatric bipolar disorder is limited. Objective: To compare the risk of all-cause and psychiatric hospitalization ...

Li Wang , MS, MBA, PhD, MA;

Daisy Ng-Mak , PhD;

Sulena Shrestha , MPH;

Aditi Kadakia , MS;

Antony Loebel , MD;

11/22/2019

Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial

Background: SEP-363856 is a novel trace amine associated receptor-1 (TAAR1)/5-HT1A agonist with no dopamine-D2/5-HT2A antagonist activity which has shown efficacy in animal models of psyc...

Antony Loebel , MD;

Justine Kent , MD;

Robert Goldman , PhD;

Hailong Cheng , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

11/22/2019

Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: Results of a 12-week Open-label Extension Study

Objective: To evaluate the efficacy and tolerability of longer-term treatment with lurasidone in patients with major depressive disorder (MDD) with mixed features.

Antony Loebel , MD;

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Stephen Stahl , MD;

Yongcai Mao , PhD;

03/01/2019

Safety and Effectiveness of Long-term Treatment With Lurasidone in Children and Adolescents With Bipolar Depression: Interim Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the long-term safety and efficacy of lurasidone in children and adolescents with bipolar depression. Methods: Patients (10-17 years) with bipolar depression who co...

Antony Loebel , MD;

Robert Goldman , PhD;

Melissa DelBellow , MD;

Andrei Pikalov , MD, PhD;

Ling Deng , PhD;

Michael Tocco , PhD;

03/01/2019

Efficacy of Lurasidone in Child and Adolescent Patients With Bipolar I Depression and Anxiety: A Post-hoc Analysis

Objective: To evaluate the efficacy of lurasidone in treating pediatric patients with bipolar depression who presented with high levels of anxiety.

Antony Loebel , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Mark Owens , DO;

03/01/2019

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: Analysis of a 2-year, Open-label Extension Study

Objective: To obtain long-term data on the safety and effectiveness of lurasidone in adolescents with schizophrenia Methods: Adolescents (13-17 years) who completed 6 weeks of double-bli...

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Antony Loebel , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

03/01/2019

Effect of Lurasidone on Cognition in Children and Adolescents With Bipolar Depression: Interim Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the long-term effects of lurasidone on cognition in children and adolescents with bipolar depression.

Ling Deng , PhD;

Katherine Burdick , PhD;

Michael Tocco , PhD;

Antony Loebel , MD;

Robert Goldman , PhD;

03/01/2019

Effect of Lurasidone on Cognition in Adolescents With Schizophrenia: Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the short and long-term effects of lurasidone on cognitive performance in adolescents with schizophrenia.

Antony Loebel , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

Philip Harvey , PhD;

Josephine Cucchiaro , PhD;

Michael Tocco , PhD;

03/01/2019

Dasotraline for Treatment of Adults With Binge-eating Disorder: Effect on Behavioral Outcomes - Week 2

Objective: To evaluate the efficacy of dasotraline in the treatment of secondary behavioral and psychological outcomes in patients with Binge-eating disorder (BED).

Antony Loebel , MD;

Robert Goldman , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

Brad Navia , MD, PhD;

James Hudson , MD;

Susan McElroy , MD;

Ling Deng , PhD;

03/01/2019